VIR stock news · Vir Biotechnology, Inc.
Get alerts for VIR
Follow Vir Biotechnology, Inc. (VIR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VIRFree on the App Store and Google Play, or on the web.
Vir Biotechnology, Inc. says it sold some of its shares without registering them.
Good for VIRVir will work with Gilead on 3 possible cancer drugs, and Gilead will invest about $25 million. The partnership supports Vir's outlook, though drug success is uncertain.
Vir Biotechnology, Inc.: Other Events (VIR)
Good for VIRVir Biotechnology received FDA Fast Track status for VIR-5500, a prostate cancer drug. This supports its development, but does not mean the drug is approved or works.
Vir Biotechnology, Inc. announced new leaders and pay plans after some directors and officers left.
NeutralVIR named an experienced finance leader as CFO. His pay and stock awards add costs, but the filing reports no new business results, leaving the outlook unchanged.